|
| | BMX-IN-1 Basic information |
| Product Name: | BMX-IN-1 | | Synonyms: | 6]naphthyridin-1(2H)-yl)phenyl)acrylamide;BMX KINASE INHIBITOR;N-(2-METHYL-5-(9-(4-(METHYLSULFONAMIDO)PHENYL)-2-OXOBENZO[H][1;6]NAPHTHYRIDIN-1(2H)-YL)PHENYL)ACRYLAMIDE;N-(2-methyl-5-(9-(4-(methylsulfonamido)phenyl)-2-oxobenzo[h][1;BMX kinase inhibitor;BMX-IN-1;N-(2-Methyl-5-(9-(4-(MethylsulfonaMido)phenyl)-2-oxobenzo[h][1,6]naphthyridin-1(2H)-yl)phenyl)acrylaMide;N-[2-Methyl-5-[9-[4-[(methylsulfonyl)amino]phenyl]-2-oxobenzo[h]-1,6-naphthyridin-1(2H)-yl]phenyl]-2-propenamide;henyl]- | | CAS: | 1431525-23-3 | | MF: | C29H24N4O4S | | MW: | 524.59 | | EINECS: | | | Product Categories: | | | Mol File: | 1431525-23-3.mol |  |
| | BMX-IN-1 Chemical Properties |
| density | 1.397±0.06 g/cm3(Predicted) | | storage temp. | Store at -20°C | | solubility | insoluble in H2O; insoluble in EtOH; ≥5.25 mg/mL in DMSO | | form | solid | | pka | 7.77±0.10(Predicted) |
| | BMX-IN-1 Usage And Synthesis |
| Description | BMX-IN-1 is a selective, irreversible inhibitor of bone marrow tyrosine kinase on chromosome X (BMX; IC50 = 8 nM) that targets Cys496 in the BMX ATP binding domain. It additionally targets the related Bruton’s tyrosine kinase (BTK) with an IC50 value of 10.4 nM, but is more than 47-656-fold less potent for inhibition of Blk, JAK3, EGFR, Itk, or Tec activity. BMX-IN-1 was shown to inhibit the proliferation of Tel-BMX-transformed Ba/F3 prostate cancer cells with a GI50 value of 25 nM. Antiproliferative activity was also observed in RV-1, DU-145, PC-3, and VCAP prostate cancer cell lines (GI50s = 2.54, 4.38, 5.37, and 2.46 μM, respectively). | | target | BMX Kinase | | storage | Store at -20°C |
| | BMX-IN-1 Preparation Products And Raw materials |
|
